TITLE

Monthly Consta Kaput; Alkermes, J&J Face Sustenna

AUTHOR(S)
Hollingsworth, Catherine
PUB. DATE
August 2009
SOURCE
BioWorld Today;8/28/2009, Vol. 20 Issue 166, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that partners Janssen LP and Alkermes Inc. have decide not to push through with plans to formulate a once-monthly version of Risperdal Consta, an antipsychotic drug. The current form of the drug is delivered by injection and is used by patients with bipolar disorder and schizophrenia. On the other hand, the Food and Drug Administration (FDA) in the U.S. gave an approval for the Invega Sustenna antipsychotic from Johnson & Johnson.
ACCESSION #
43942783

 

Related Articles

  • Risperdal Consta update.  // MPR - Residents' Edition;Fall/Winter2009, Vol. 18 Issue 2, pA7 

    The article reports on the approval of the new monotherapy or adjuvant therapy Risperdal Consta from Janssen Pharmaceutica NV in the maintenance treatment of bipolar I disorder by the U.S. Food and Drug Administration (FDA). It mentions that the drug is a risperidone long-acting injection and it...

  • A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Caccia, Silvio; Invernizzi, Roberto William; Nobili, Alessandro; Pasina, Luca // Therapeutics & Clinical Risk Management;2013, Vol. 9, p319 

    Cariprazine is a potential antipsychotic awaiting approval from the US Food and Drug Administration. It is a dopamine D2- and D3-receptor partial agonist, with higher affinity for D3 receptors, as opposed to the D2 antagonism of most older antipsychotic agents. Like most lipophilic...

  • FDA Actions. Elliott, William T. // Clinical Cardiology Alert;Nov2009 Pharmacology Watch, p2 

    This section offers news briefs concerning the Food and Drug Administration (FDA) in the U.S. Asenapine has been given approval by the FDA as cure for schizophrenia and bipolar I disorder in adults. The FDA also reduced the approved age limit for levocetirizine to 6 months for children suffering...

  • FDA Actions. Elliott, William T. // Primary Care Reports;Nov2009 Pharmacology Watch, p2 

    The article presents updates about the drug approval decisions of the U.S. Food and Drug Administration (FDA). Asenaphine has been approved for treating schizophrenia and bipolar I disorder in adults. This is expected to carry a warning regarding increased mortality in elderly patients with...

  • FDA Actions. Elliott, William T. // Clinical Oncology Alert;Nov2009 Supplement, p2 

    This section offers news briefs concerning the Food and Drug Administration (FDA) in the U.S. Asenapine has been given approval by the FDA as cure for schizophrenia and bipolar I disorder in adults. The FDA also reduced the approved age limit for levocetirizine to 6 months for children suffering...

  • FDA Actions. Elliott, William T. // Neurology Alert;Nov2009 Pharmacology Watch, p2 

    This section offers news briefs concerning the Food and Drug Administration (FDA) in the U.S. Asenapine has been given approval by the FDA as cure for schizophrenia and bipolar I disorder in adults. The FDA also reduced the approved age limit for levocetirizine to 6 months for children suffering...

  • FDA Issues CRL for Alexza Pharmaceuticals' Adasuve. Shaffer, Catherine // BioWorld Today;5/7/2012, Vol. 23 Issue 88, p1 

    This article reports on the decision of the U.S. Food and Drug Administration (FDA) to issue a complete response letter for Alexza Pharmaceuticals Inc.'s Adasuve inhalation powder for agitation in schizophrenia and bipolar disorder. According to the company, the agency cited manufacturing...

  • Sunovion: Latuda poised to expand options in bipolar depression.  // PharmaWatch: CNS;Dec2012, Vol. 11 Issue 12, p14 

    The article reports on the plan of Sunovion to expand options for the drug Latuda for depressive episodes in bipolar disorder. It cited the decision of the U.S. Food and Drug Administration (FDA) to review two supplemental New Drug Applications (sNDAs) for use of the drug as monotherapy and...

  • Fanapt.  // Pharmaceutical Representative;Jul2009, Vol. 39 Issue 7, p11 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Fanapt (Iloperidone) from Vanda Pharmaceuticals Inc. to treat schizophrenia. It notes that the drug was first developed by Hoechst and licensed to Titan Pharmaceuticals. The company plans to make the drug...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics